Raymond James reiterates Outperform rating on AxoGen stock despite FDA delay – RP Digital

Business

Raymond James reiterates Outperform rating on AxoGen stock despite FDA delay

August 25, 20251 min0

Raymond James reiterates Outperform rating on AxoGen stock despite FDA delay

Source link

rpdigital

Leave a Reply Cancel reply

Related Articles

BancFirst declares quarterly dividend and trust interest payment

rpdigitalAugust 28, 20250

Jefferies raises Ollie's Bargain Outlet stock price target to $135 on strong growth

rpdigitalAugust 28, 20250